Information on EC 3.2.1.45 - glucosylceramidase and Organism(s) Homo sapiens

for references in articles please use BRENDA:EC3.2.1.45
Word Map on EC 3.2.1.45
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
This record set is specific for:
Homo sapiens


The expected taxonomic range for this enzyme is: Eukaryota, Bacteria


The taxonomic range for the selected organisms is: Homo sapiens

EC NUMBER
COMMENTARY hide
3.2.1.45
-
RECOMMENDED NAME
GeneOntology No.
glucosylceramidase
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of O-glycosyl bond
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Other glycan degradation
-
-
Sphingolipid metabolism
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
D-glucosyl-N-acylsphingosine glucohydrolase
Also acts on glucosylsphingosine (cf. EC 3.2.1.62 glycosylceramidase).
CAS REGISTRY NUMBER
COMMENTARY hide
37228-64-1
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-glucosylceramide + H2O
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)sphingosine + D-glucose
show the reaction diagram
-
-
-
-
?
12(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminododecanoyl-2-N-sphingosyl 1-O-beta-D-glucoside + H2O
D-glucose + 12(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminododecanoyl-2-N-sphingosine
show the reaction diagram
3-O-benzoyl-N-stearylglucosphingosine + H2O
D-glucose + 3-O-benzoyl-N-stearylsphingosine
show the reaction diagram
-
not: galactocerebroside
-
-
?
4-methylumbelliferyl beta-D-glucopyranoside + H2O
4-methylumbelliferone + beta-D-glucopyranose
show the reaction diagram
-
-
-
-
?
4-methylumbelliferyl glucoside + H2O
4-methylumbelliferone + D-glucose
show the reaction diagram
-
-
-
-
?
4-methylumbelliferyl-beta-D-galactopyranoside + H2O
methylumbelliferone + beta-D-galactose
show the reaction diagram
-
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
4-methylumbelliferone + beta-D-glucose
show the reaction diagram
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
methylumbelliferone + beta-D-glucose
show the reaction diagram
-
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
methylumbelliferone + glucose
show the reaction diagram
4-methylumbelliferyl-beta-D-glucoside + H2O
4-methylumbelliferone + beta-D-glucose
show the reaction diagram
-
-
-
-
?
4-nitrophenyl beta-D-glucopyranoside + H2O
4-nitrophenol + D-glucopyranose
show the reaction diagram
-
-
-
-
?
6(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexyl-2-N-sphingosyl 1-O-beta-D-glucoside + H2O
D-glucose + 6(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexyl-2-N-sphingosine
show the reaction diagram
6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-galactosylceramide + H2O
6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)ceramide + D-galactose
show the reaction diagram
-
-
-
-
?
6-[N-methyl-N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)aminododecanoyl]sphingosyl-beta-D-glucoside + H2O
?
show the reaction diagram
-
-
-
-
?
C18-galactosylceramide + H2O
?
show the reaction diagram
-
-
-
-
?
C18-glucosylceramide + H2O
?
show the reaction diagram
-
-
-
-
?
D-glucocerebroside + H2O
D-glucose + ceramide
show the reaction diagram
-
-
-
-
?
D-glucosyl-beta-(1-1')-N-dodecanoyl-D-erythro-sphingosine + H2O
D-glucose + N-dodecanoyl-D-erythro-sphingosine
show the reaction diagram
-
product and internal standard are quantified using tandem mass spectrometry
-
-
?
D-glucosyl-N-butylsphingosine + H2O
D-glucose + N-butylsphingosine
show the reaction diagram
-
-
-
-
?
D-glucosyl-N-ethylsphingosine + H2O
D-glucose + N-ethylsphingosine
show the reaction diagram
-
-
-
-
?
D-glucosyl-N-methylsphingosine + H2O
D-glucose + N-methylsphingosine
show the reaction diagram
-
-
-
-
?
D-glucosyl-N-octylsphingosine + H2O
D-glucose + N-octylsphingosine
show the reaction diagram
-
-
-
-
?
D-glucosyl-N-propylsphingosine + H2O
D-glucose + N-propylsphingosine
show the reaction diagram
-
-
-
-
?
glucocerebroside + H2O
beta-D-glucose + ceramide
show the reaction diagram
-
-
-
-
?
glucocerebroside + H2O
ceramide + D-glucose
show the reaction diagram
-
-
-
-
?
glucocerebroside + H2O
glucose + ceramide
show the reaction diagram
glucosylceramide + H2O
beta-D-glucose + ceramide
show the reaction diagram
N-(6-(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-D-erythro-glucosylsphingosine + H2O
D-glucose + N-(6-(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-sphingosine
show the reaction diagram
-
-
-
-
?
N-palmitoyl-dihydroglucocerebroside + H2O
D-glucose + N-palmitoyl-dihydrocerebroside
show the reaction diagram
-
-
-
-
?
N-stearoyl-dihydroglucocerebroside + H2O
D-glucose + N-stearoyl-dihydrocerebroside
show the reaction diagram
-
-
-
-
?
N-stearoylglucosyl ceramide + H2O
D-glucose + stearoylceramide
show the reaction diagram
-
-
-
-
?
nonylumbelliferyl-beta-D-glucopyranoside + H2O
nonylumbelliferone + glucose
show the reaction diagram
-
-
-
-
?
palmitylglucosyl ceramide + H2O
D-glucose + palmitylceramide
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
glucocerebroside + H2O
ceramide + D-glucose
show the reaction diagram
-
-
-
-
?
glucocerebroside + H2O
glucose + ceramide
show the reaction diagram
glucosylceramide + H2O
beta-D-glucose + ceramide
show the reaction diagram
-
-
-
-
?
additional information
?
-
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R,2R,3S,4S,5R,6S)-7-oxabicyclo[4.1.0]heptane-2,3,4,5-tetrol
-
-
(2R,3R,4R,5S)-1-(5-[[3',5'-bis(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(1,3-benzodioxol-5-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(2-fluoropyridin-4-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(6-fluoropyridin-3-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(biphenyl-2-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(biphenyl-3-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(hexyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(1R)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(1S)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(2'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(2-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(3'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(3-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(3beta,17alpha,20S)-cholestan-3-yloxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(4'-chlorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(4'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4'-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-3-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-4-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyrimidin-5-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(4,6,8a,10c-tetrahydropyren-1-ylmethoxy)pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(naphthalen-2-ylmethoxy)pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(phenanthren-9-ylmethoxy)pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5-phenylpyridin-2-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5R)-octahydro-1H-2,5-methanoinden-6-ylmethoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]hexyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]hexyl]piperidine-3,4,5-triol
-
-
(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3S,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3S,4R,5S)-2-(hydroxymethyl)-1-[5-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]pentyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(8a,10c-dihydropyren-1-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(biphenyl-2-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(biphenyl-3-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(hexyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(1R)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(1S)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(2-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(3-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(3beta,17alpha,20S)-cholest-5-en-3-yloxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[(5Z)-6-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]hex-5-en-1-yl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(naphthalen-2-ylmethoxy)pentyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(phenanthren-9-ylmethoxy)pentyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(1R,5S)-tricyclo[3.3.1.13,7]dec-2-ylmethoxy]pentyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]hexyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3S)-tricyclo[3.3.1.13,7]dec-1-yl]hexyl]piperidine-3,4,5-triol
-
-
(3aR,4S,5R,6R,7S,7aS)-2-(3-phenylpropylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
-
(3aR,4S,5R,6R,7S,7aS)-2-(nonylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
-
(3aR,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aR,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aR,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aR,4S,5R,6S,7R,7aS)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aR,4S,5S,6S,7R,7aR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aR,4S,5S,6S,7R,7aR)-4-(benzyloxy)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aRS,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aS,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aS,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aS,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aS,4S,5R,6S,7R,7aS)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aS,4S,5S,6S,7R,7aS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
-
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
1,4-dideoxy-1,4-imino-D-arabinitol
-
-
1,5-dideoxy-1,5-iminoxylitol
-
potent inhibitor
1-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)-3-phenylpropan-2-ol
-
-
1-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)propan-2-ol
-
-
1-[3-[(5-bromopyridin-2-yl)(3,4-dichlorobenzyl)amino]propyl]-3-[3-(1H-imidazol-4-yl)propyl]thiourea
-
-
2,2'-([4-[(5-chloro-2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]imino)diethanol
-
-
2-(4-(5-chloro-2-methoxyphenylamino)-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-ylamino)ethanol
-
-
2-([4-(3,3-difluoropyrrolidin-1-yl)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-(benzylamino)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-(butylamino)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-azetidin-1-yl-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2,4-dimethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2,5-dimethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-ethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)benzamide
-
-
2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
-
-
2-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)acetamide
-
-
2-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-nitrophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-phenoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-tert-butoxy-5-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-tert-butoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(3-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(3-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(3-methylphenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(3-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(4-chlorophenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(4-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(4-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(4-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-benzyl-2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-ethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-(diethylamino)-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-azepan-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-piperidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-[(4-pyrrolidin-1-yl-6-[[2-(trifluoromethoxy)phenyl]amino]-1,3,5-triazin-2-yl)amino]ethanol
-
-
2-[(4-[[2-(benzyloxy)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
-
-
2-[(4-[[2-(methylsulfanyl)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
-
-
2-[(4-[[2-methoxy-5-(trifluoromethyl)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
-
-
2-[(4-[[5-chloro-2-(1-methylethoxy)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
-
-
2-[[4-(phenylamino)-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino]ethanol
-
-
2-[[4-(prop-2-en-1-ylamino)-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino]ethanol
-
-
2R,5R-dihydroxymethyl-3R,4R-dihydroxypyrrolidine
-
-
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-2-carbonitrile
-
-
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-3-carbonitrile
-
-
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-4-carbonitrile
-
-
4-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)butan-1-ol
-
-
4-benzyl-2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
-
-
4-chloro-2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
-
-
4-eicosan-sphingenine
-
-
-
4-hexadecyl-sphingenine
-
-
-
4-methyl-N-(4-methyl-2-morpholin-4-ylquinolin-6-yl)cyclohexanecarboxamide
-
-
4-methyl-N-(4-methyl-2-piperidin-1-ylquinolin-6-yl)cyclohexanecarboxamide
-
-
4-methyl-N-[4-methyl-2-(4-methylpiperidin-1-yl)quinolin-6-yl]cyclohexanecarboxamide
-
-
4-methyl-N-[4-methyl-2-(4-pyrimidin-4-ylpiperazin-1-yl)-1,2-dihydroquinolin-6-yl]cyclohexanecarboxamide
-
-
4-O-(beta-D-glucopyranosyl)-N-butyl-2-O-butyl-1,5-dideoxy-1,5-imino-D-glucitol
-
-
4-octadecyl-sphingenine
-
-
-
4-octadecyl-threo-sphingenine
-
-
-
4-sphingenine
-
-
4-tetradecyl-sphingenine
-
-
-
4-undecyl-sphingenine
-
-
-
4-[4-(cyanomethoxy)phenyl]-4-oxo-N-{3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propyl}butanamide
-
-
4-[4-(naphthalen-2-ylsulfonyl)piperazin-1-yl]-2-(thiophen-2-yl)quinazoline
-
-
4-[[(4-chlorophenyl)sulfonyl]amino]-N-(2,5-dihydro-1,3-thiazol-2-yl)benzamide
-
-
5-((4-methylphenyl)thio)-quinazoline 2,4-diamine
-
inhibition of wild-type enzyme and chaperone function on mutant enzyme. Treated fibroblasts from patients with Gaucher disease show decreased levels of enzyme in their endoplasmic reticulum and increased levels in lysosomes. Compound stabilizes a domain III active-site loop
5-(3,5-dichlorophenoxy)-N-(4-pyridinyl)-2-furamide
-
inhibition of wild-type enzyme and chaperone function on mutant enzyme. Treated fibroblasts from patients with Gaucher disease show decreased levels of enzyme in their endoplasmic reticulum and increased levels in lysosomes. Compound stabilizes a domain III active-site loop
5-N,6-O-[N'-(n-octyl)iminomethylidene]nojirimycin
-
potent inhibitor
-
5-N,6-S-[N'-(n-octyl)iminomethylidene]-6-thionojirimycin
-
potent inhibitor
6-amino-6-deoxy-5-N,6-N-[N'-(n-octyl)iminomethylidene]nojirimycin
-
-
-
6-bromo-6-deoxy-conduritol
-
-
6-bromo-conduritol-beta-epoxide
-
-
alkyl amines
-
-
Alkyl beta-glucosides
-
-
alpha-1-C-butyl-1-deoxynojirimycin
-
-
alpha-1-C-hexyl-1-deoxyimino-D-xylitol
-
-
alpha-1-C-hexyl-1-deoxynojirimycin
-
-
alpha-1-C-nonyl-1-deoxyimino-D-xylitol
-
strong inhibitor
alpha-1-C-propyl-1-deoxyimino-D-xylitol
-
-
alpha-1-C-propyl-1-deoxynojirimycin
-
-
beta-1-C-butyl-1,5-dideoxy-1,5-imino-L-iditol
-
-
beta-1-C-hexyl-1,5-dideoxy-1,5-imino-L-iditol
-
-
beta-1-C-propyl-1,5-dideoxy-1,5-imino-L-iditol
-
-
calystegine A3
-
potent inhibitor
calystegine A5
-
-
calystegine B1
calystegine B2
calystegine B3
-
-
calystegine B4
-
-
calystegine C1
castanospermine
-
-
chondroitin sulfate
-
-
conduritol B epoxide
conduritol B-epoxide
-
-
conduritol-B-epoxide
-
irreversible
Dextran sulfate
-
-
-
glucal
-
-
gluconolactone
-
-
glucose
-
at 220 mM
glucosylsphingosine
-
-
glycosylamine
-
-
-
iminoglycolipid
-
-
-
isofagomine
methyl ([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)acetate
-
-
miglitol
-
-
miglustat
-
-
Monoclonal antibodies
-
100% inhibition with F1 and F2, 60% inhibition with no. 61
-
N-(2,5-dihydro-1,3-thiazol-2-yl)-4-[methyl(phenylsulfonyl)amino]benzamide
-
-
N-(4-methyl-2-morpholin-4-ylquinolin-6-yl)-4-propylcyclohexanecarboxamide
-
-
N-(4-methyl-2-morpholin-4-ylquinolin-6-yl)cyclopropanecarboxamide
-
-
N-(4-methyl-2-morpholinoquinolin-6-yl)cyclohexanecarboxamide
-
-
N-(5-adamantane-1-yl-methoxy)pentyl-deoxynojirimycin
-
extremely potent inhibitor for GBA2
N-(5-chloro-2-methoxyphenyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
-
-
N-(5-chloro-2-methoxyphenyl)-N'-(2-methoxyethyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
-
-
N-(5-chloro-2-methoxyphenyl)-N'-(furan-2-ylmethyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
-
-
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-(phenylsulfonamido)benzamide
-
-
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-[(phenylsulfonyl)amino]benzamide
-
-
N-(5-ethyl-1,3,4-thiadiazolidin-2-yl)-4-[methyl(phenylsulfonyl)amino]benzamide
-
-
N-(5-methylisoxazol-3-yl)-4-(phenylsulfonamido)benzamide
-
-
N-(5-methylisoxazol-3-yl)-4-[methyl(phenylsulfonyl)amino]benzamide
-
-
N-benzyl-4-[(phenylsulfonyl)amino]benzamide
-
-
N-benzyl-N'-(5-chloro-2-methoxyphenyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
-
-
N-butyl-1-deoxynojirimycin
-
-
N-butyl-4-[(phenylsulfonyl)amino]benzamide
-
-
N-butyl-deoxynojirimycin
N-butyl-N'-(5-chloro-2-methoxyphenyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
-
-
N-butyldeoxynojirimycin
N-butylisofagomine
-
-
N-decyl-1-deoxynojirimycin
-
-
N-decylglycosylamine
-
-
N-dodecyl-1-deoxynojirimycin
N-dodecylglycosylamine
-
-
N-hexadecylglycosylamine
-
-
N-hexyl-D-glucosylsphingosine
-
-
N-hexylglycosylamine
-
-
N-hydroxy-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
-
-
N-methyl-1-deoxynojirimycin
-
-
N-methylcalystegine B2
-
-
N-nonyl-1-deoxynojirimycin
-
-
N-nonyl-deoxynojirimycin
-
-
N-nonyldeoxynojirimycin
-
-
N-octadecylglycosylamine
-
-
N-octylglycosylamine
-
-
N-phenyl-4-[(phenylsulfonyl)amino]benzamide
-
-
N-tetradecyl-1-deoxynojirimycin
-
-
N-tetradecylglycosylamine
-
-
N-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]-6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
-
-
N-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]-6-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
-
-
N-[2-(3,6-dihydropyridin-1(2H)-yl)-4-methylquinolin-6-yl]cyclohexanecarboxamide
-
-
N-[2-(diethylamino)-4-methyl-1,2-dihydroquinolin-6-yl]-4-methylcyclohexanecarboxamide
-
-
N-[2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenyl]acetamide
-
-
N-[2-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethyl]acetamide
-
-
N-[2-[(3-chlorophenyl)amino]-4-methyl-1,2-dihydroquinolin-6-yl]-4-methylcyclohexanecarboxamide
-
-
N-[5-(adamantan-1-yl-methoxy)pentyl]-L-ido-1-deoxynojirimycin
-
-
N-{3-[4-(cyanomethoxy)benzoyl]benzoyl}propylamido-1-deoxynojirimycin
-
-
nojirimycin bisulfite
-
-
p-hydroxymercuribenzoate
-
weak
saposin C
-
-
-
SO42-
-
-
Triton X-100
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(3aR,4S,5R,6R,7S,7aS)-2-(3-phenylpropylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.9fold and 1.4fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aR,4S,5R,6R,7S,7aS)-2-(nonylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.8fold and 1.4fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aR,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.8fold and 1.4fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aR,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.7fold and 1.3fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.7fold in N370S lymphoblasts from Gaucher patients
(3aS,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.4fold and 1.1fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aS,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 2.1fold and 1.5fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.7fold in N370S lymphoblasts from Gaucher patients
celastrol
-
significantly increases the quantity and catalytic activity of the enzyme by reducing protein degradation
dexamethasone
-
the pretreatment with dexamethasone has the effect of selectively increasing the uptake of wild-type and recombinant enzymes by the macrophages but not by the liver sinusoidal endothelial cells or hepatocyte cells in vitro, the dexamethasone pre-treatment increases the uptake of enzyme by kupffer cells and by splenic macrophages in vivo.
glycoprotein
-
heat-stable
heat-stable factor
-
-
-
isofagomine
-
GlcCerase activity is enhanced in normal fibroblasts 1.3fold after treatment with 0.03 mM isofagomine for 5 days
monoclonal antibody
-
no. 122 mimicking the effect of saposin C
-
N-(n-butyl)deoxynojirimycin
-
other names are miglustat and Zavesca, about 20% increase of wild type enzyme activity at 0.0025 and 0.005 mM
N-(n-nonyl) deoxynojirimycin
-
1.3-1.4fold increase in activity is observed for the wild type enzyme at 0.02 mM
N-nonyl-deoxynojirimycin
-
Gcase activity increase: 1.9fold in N370S lymphoblasts from Gaucher patients
phosphatidylglycerol
phosphatidylinositol
-
acidic, unsaturated phospholipid interfaces interact with acid beta-glucosidase to conform the enzyme into an active structure
phosphatidylserine
Phospholipid
-
the full catalytic activity requires phospholipid interfaces
saposin C
-
saposin-A
-
saposin-C
-
sodium taurocholate
sodium taurodeoxycholate
-
-
Triton X-100
-
-
additional information
-
The reconstruction of the activity of lysosomal enzyme requires phospholipids and a protein factor: saposin C. The hydrophobic properties of saposin C are regulated by the pH of the environment. The interaction of saposin C with membranes is affected by the content of anionic phospholipids
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00204
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-galactosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.00464
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-glucosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.05
12(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexyl-2-N-sphingosyl 1-O-beta-D-glucoside
-
-
1.06 - 1.127
4-methylumbelliferyl beta-D-glucopyranoside
0.1445
4-methylumbelliferyl-beta-D-galactopyranoside
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.04928 - 4
4-methylumbelliferyl-beta-D-glucopyranoside
2.331 - 2.592
4-nitrophenyl beta-D-glucopyranoside
0.17
4-nonylumbelliferyl-beta-D-glucopyranoside
-
-
0.03
6(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexanoyl-2-N-sphingosyl 1-O-beta-D-glucoside
-
-
0.03 - 0.65
beta-D-glucocerebroside
0.00924
C18-galactosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.01367
C18-glucosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.042
D-glucosyl-N-butylsphingosine
-
-
0.032
D-glucosyl-N-ethylsphingosine
-
-
0.014
D-glucosyl-N-methylsphingosine
-
-
0.033
D-glucosyl-N-octylsphingosine
-
-
0.02
D-glucosyl-N-propylsphingosine
-
-
0.015 - 0.247
glucosylceramide
0.034
palmitylglucosyl ceramide
-
-
-
0.028
stearylglucosyl ceramide
-
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.03
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-galactosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.12
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-glucosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
1.57
4-methylumbelliferyl-beta-D-galactopyranoside
-
in 50 mM MES buffer, pH 6.0, at 37°C
1.23
4-methylumbelliferyl-beta-D-glucopyranoside
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.007
C18-glucosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
31.67 - 35
glucosylceramide
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00001
(3aR,4S,5R,6R,7S,7aS)-2-(3-phenylpropylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.000003
(3aR,4S,5R,6R,7S,7aS)-2-(nonylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0018
(3aR,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0048
(3aR,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0015
(3aR,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0088
(3aR,4S,5S,6S,7R,7aR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.0111
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.00044
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0017
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0024
(3aRS,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0259
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.00053
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.0036
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.00004
(3aS,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0125
(3aS,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.000002
(3aS,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0028
(3aS,4S,5R,6S,7R,7aS)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.00018
(3aS,4S,5S,6S,7R,7aS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.0034
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.00007
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.00023
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.00004
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
-
0.000002
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.000007
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0013
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.00047
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.00013
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
2.2
alpha-1-C-nonyl-1-deoxyimino-D-xylitol
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.0005 - 0.0015
calystegine B1
0.0009
calystegine C1
-
pH 4.5, 37°C
0.0003
N-nonyl-deoxynojirimycin
-
pH 5.2, 37°C
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0167
(1R,2R,3S,4S,5R,6S)-7-oxabicyclo[4.1.0]heptane-2,3,4,5-tetrol
Homo sapiens
-
-
0.000015 - 0.0008
(2R,3R,4R,5S)-1-(5-[[3',5'-bis(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0005
(2R,3R,4R,5S)-1-(5-[[4-(1,3-benzodioxol-5-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.00003 - 0.00025
(2R,3R,4R,5S)-1-(5-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000004 - 0.002
(2R,3R,4R,5S)-1-(5-[[4-(2-fluoropyridin-4-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000015 - 0.003
(2R,3R,4R,5S)-1-(5-[[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000005 - 0.003
(2R,3R,4R,5S)-1-(5-[[4-(6-fluoropyridin-3-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.0003
(2R,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.00125
(2R,3R,4R,5S)-1-[5-(biphenyl-2-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0003
(2R,3R,4R,5S)-1-[5-(biphenyl-3-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.00001 - 0.000125
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.0003
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0004
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000004 - 0.0015
(2R,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.0003
(2R,3R,4R,5S)-1-[5-[(1R)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.4
(2R,3R,4R,5S)-1-[5-[(1S)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0006
(2R,3R,4R,5S)-1-[5-[(2'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.00000008 - 0.0002
(2R,3R,4R,5S)-1-[5-[(2-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.00025
(2R,3R,4R,5S)-1-[5-[(3'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.00000008 - 0.00025
(2R,3R,4R,5S)-1-[5-[(3-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000005 - 0.0005
(2R,3R,4R,5S)-1-[5-[(3beta,17alpha,20S)-cholestan-3-yloxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0005
(2R,3R,4R,5S)-1-[5-[(4'-chlorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.0004
(2R,3R,4R,5S)-1-[5-[(4'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.0001 - 0.0025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
0.00000008 - 0.0001
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
0.00000012 - 0.0002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
0.00001 - 0.0008
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4'-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
0.00001 - 0.003
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-3-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
0.00001 - 0.002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-4-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
0.000025 - 0.01
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyrimidin-5-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
0.000003 - 0.0005
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(4,6,8a,10c-tetrahydropyren-1-ylmethoxy)pentyl]piperidine-3,4,5-triol
0.000001 - 0.001
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(naphthalen-2-ylmethoxy)pentyl]piperidine-3,4,5-triol
0.0001 - 0.01
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(phenanthren-9-ylmethoxy)pentyl]piperidine-3,4,5-triol
0.000003 - 0.0006
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.0000005 - 0.00007
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.00002 - 0.0025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.000002 - 0.00025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.00001 - 0.0025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.000003 - 0.00025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.000003 - 0.0015
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5-phenylpyridin-2-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.000001 - 0.0004
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5R)-octahydro-1H-2,5-methanoinden-6-ylmethoxy]pentyl]piperidine-3,4,5-triol
0.000002 - 0.0001
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]hexyl]piperidine-3,4,5-triol
0.00001 - 0.00006
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]hexyl]piperidine-3,4,5-triol
0.0003 - 0.32
(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.2
(2R,3S,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.0002
(2R,3S,4R,5S)-2-(hydroxymethyl)-1-[5-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]pentyl]piperidine-3,4,5-triol
0.00025
(2S,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.000001 - 0.015
(2S,3R,4R,5S)-1-[5-(8a,10c-dihydropyren-1-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.01
(2S,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.015
(2S,3R,4R,5S)-1-[5-(biphenyl-2-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.02
(2S,3R,4R,5S)-1-[5-(biphenyl-3-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.5
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0125
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.02
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000006 - 0.06
(2S,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.01
(2S,3R,4R,5S)-1-[5-[(1R)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.01
(2S,3R,4R,5S)-1-[5-[(1S)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.0000006 - 0.006
(2S,3R,4R,5S)-1-[5-[(2-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.0000004 - 0.008
(2S,3R,4R,5S)-1-[5-[(3-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000005 - 0.015
(2S,3R,4R,5S)-1-[5-[(3beta,17alpha,20S)-cholest-5-en-3-yloxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.0001 - 0.05
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
0.0000001 - 0.006
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
0.0000001 - 0.005
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
0.000008 - 0.012
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[(5Z)-6-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]hex-5-en-1-yl]piperidine-3,4,5-triol
0.000001 - 0.05
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(naphthalen-2-ylmethoxy)pentyl]piperidine-3,4,5-triol
0.0002 - 0.6
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(phenanthren-9-ylmethoxy)pentyl]piperidine-3,4,5-triol
0.000002 - 0.01
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(1R,5S)-tricyclo[3.3.1.13,7]dec-2-ylmethoxy]pentyl]piperidine-3,4,5-triol
0.0000025 - 0.005
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]hexyl]piperidine-3,4,5-triol
0.00002 - 0.025
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3S)-tricyclo[3.3.1.13,7]dec-1-yl]hexyl]piperidine-3,4,5-triol
0.00001 - 0.00004
(3aR,4S,5R,6R,7S,7aS)-2-(3-phenylpropylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
0.000004 - 0.00001
(3aR,4S,5R,6R,7S,7aS)-2-(nonylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
0.0017 - 0.006
(3aR,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0012 - 0.0104
(3aR,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00032 - 0.0019
(3aR,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0567 - 0.16
(3aR,4S,5R,6S,7R,7aS)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0173
(3aR,4S,5S,6S,7R,7aR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.157
(3aR,4S,5S,6S,7R,7aR)-4-(benzyloxy)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.0044 - 0.0129
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00019 - 0.00071
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00054 - 0.0025
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0006 - 0.0029
(3aRS,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0644
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.0013
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.0064
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.00002 - 0.00012
(3aS,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0056 - 0.0111
(3aS,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.000005 - 0.000008
(3aS,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0024 - 0.0068
(3aS,4S,5R,6S,7R,7aS)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00035
(3aS,4S,5S,6S,7R,7aS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.0016 - 0.0064
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00004 - 0.00022
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00008 - 0.0006
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00004 - 0.0001
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
0.000008 - 0.000009
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00001 - 0.0002
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0039
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.0017
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.00074
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.16
1,4-dideoxy-1,4-imino-D-arabinitol
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.0023
1,5-dideoxy-1,5-iminoxylitol
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.0068
1-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)-3-phenylpropan-2-ol
Homo sapiens
-
-
0.0207
1-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)propan-2-ol
Homo sapiens
-
-
0.0288 - 0.506
1-deoxynojirimycin
0.00071
1-[3-[(5-bromopyridin-2-yl)(3,4-dichlorobenzyl)amino]propyl]-3-[3-(1H-imidazol-4-yl)propyl]thiourea
Homo sapiens
-
pH 5.9, at 22°C
0.00043 - 0.0007
2-(4-(5-chloro-2-methoxyphenylamino)-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-ylamino)ethanol
0.0075
2-([4-(3,3-difluoropyrrolidin-1-yl)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0188
2-([4-(benzylamino)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0061
2-([4-(butylamino)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00231
2-([4-azetidin-1-yl-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0049
2-([4-[(2,4-dimethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00153
2-([4-[(2,5-dimethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.02897
2-([4-[(2-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00077
2-([4-[(2-ethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.002
2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
Homo sapiens
-
-
0.00108
2-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00394
2-([4-[(2-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0314
2-([4-[(2-phenoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00104
2-([4-[(2-tert-butoxy-5-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00033
2-([4-[(2-tert-butoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00669
2-([4-[(3-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00825
2-([4-[(3-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0477
2-([4-[(3-methylphenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00431 - 0.00619
2-([4-[(3-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
0.0465
2-([4-[(4-chlorophenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00634 - 0.00773
2-([4-[(4-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
0.0088
2-([4-[(4-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.01004
2-([4-[(4-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00222
2-([4-[(5-benzyl-2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00096
2-([4-[(5-chloro-2-ethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0004
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
pH 5.9, at 22°C
0.01213
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0311
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-piperidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00334
2-[(4-pyrrolidin-1-yl-6-[[2-(trifluoromethoxy)phenyl]amino]-1,3,5-triazin-2-yl)amino]ethanol
Homo sapiens
-
-
0.02167
2-[(4-[[2-(benzyloxy)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
Homo sapiens
-
-
0.00239
2-[(4-[[2-(methylsulfanyl)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
Homo sapiens
-
-
0.00265
2-[(4-[[2-methoxy-5-(trifluoromethyl)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
Homo sapiens
-
-
0.00344
2-[(4-[[5-chloro-2-(1-methylethoxy)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
Homo sapiens
-
-
0.01647
2-[[4-(phenylamino)-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino]ethanol
Homo sapiens
-
-
0.28
2R,5R-dihydroxymethyl-3R,4R-dihydroxypyrrolidine
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.000005 - 0.0006
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-2-carbonitrile
0.000002 - 0.0007
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-3-carbonitrile
0.000003 - 0.00035
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-4-carbonitrile
0.00037
4-benzyl-2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
Homo sapiens
-
-
0.00073
4-chloro-2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
Homo sapiens
-
-
0.000063
4-methyl-N-(4-methyl-2-morpholin-4-ylquinolin-6-yl)cyclohexanecarboxamide
Homo sapiens
-
-
0.000452
4-methyl-N-(4-methyl-2-piperidin-1-ylquinolin-6-yl)cyclohexanecarboxamide
Homo sapiens
-
-
0.000268
4-methyl-N-[4-methyl-2-(4-methylpiperidin-1-yl)quinolin-6-yl]cyclohexanecarboxamide
Homo sapiens
-
-
0.00245
4-methyl-N-[4-methyl-2-(4-pyrimidin-4-ylpiperazin-1-yl)-1,2-dihydroquinolin-6-yl]cyclohexanecarboxamide
Homo sapiens
-
-
0.000075 - 0.00165
4-[4-(cyanomethoxy)phenyl]-4-oxo-N-{3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propyl}butanamide
0.0089
4-[4-(naphthalen-2-ylsulfonyl)piperazin-1-yl]-2-(thiophen-2-yl)quinazoline
Homo sapiens
-
pH 5.9, at 22°C
0.00129
4-[[(4-chlorophenyl)sulfonyl]amino]-N-(2,5-dihydro-1,3-thiazol-2-yl)benzamide
Homo sapiens
-
-
0.0078
5-((4-methylphenyl)thio)-quinazoline 2,4-diamine
Homo sapiens
-
pH 5.5, 37°C
0.0047
5-(3,5-dichlorophenoxy)-N-(4-pyridinyl)-2-furamide
Homo sapiens
-
pH 5.5, 37°C
0.1
alpha-1-C-butyl-1-deoxynojirimycin
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.000019
alpha-1-C-hexyl-1-deoxyimino-D-xylitol
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.0042
alpha-1-C-hexyl-1-deoxynojirimycin
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.00056
alpha-1-C-propyl-1-deoxyimino-D-xylitol
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.4
alpha-1-C-propyl-1-deoxynojirimycin
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.147
beta-1-C-butyl-1,5-dideoxy-1,5-imino-L-iditol
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.043
beta-1-C-hexyl-1,5-dideoxy-1,5-imino-L-iditol
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.487
beta-1-C-propyl-1,5-dideoxy-1,5-imino-L-iditol
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.0031
calystegine A3
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.031
calystegine A5
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.0025
calystegine B1
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.001
calystegine B2
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.076
calystegine B3
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.082
calystegine B4
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.0025
calystegine C1
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.019
castanospermine
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.000005 - 0.2
isofagomine
0.0344
N-(2,5-dihydro-1,3-thiazol-2-yl)-4-[methyl(phenylsulfonyl)amino]benzamide
Homo sapiens
-
-
0.000133
N-(4-methyl-2-morpholin-4-ylquinolin-6-yl)-4-propylcyclohexanecarboxamide
Homo sapiens
-
-
0.000183
N-(4-methyl-2-morpholin-4-ylquinolin-6-yl)cyclopropanecarboxamide
Homo sapiens
-
-
0.000031
N-(4-methyl-2-morpholinoquinolin-6-yl)cyclohexanecarboxamide
Homo sapiens
-
-
0.00007 - 0.000103
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-(phenylsulfonamido)benzamide
0.0001
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-[(phenylsulfonyl)amino]benzamide
Homo sapiens
-
pH 5.9, at 22°C
0.00296
N-(5-ethyl-1,3,4-thiadiazolidin-2-yl)-4-[methyl(phenylsulfonyl)amino]benzamide
Homo sapiens
-
-
0.000168
N-(5-methylisoxazol-3-yl)-4-(phenylsulfonamido)benzamide
Homo sapiens
-
-
0.0252
N-(5-methylisoxazol-3-yl)-4-[methyl(phenylsulfonyl)amino]benzamide
Homo sapiens
-
-
0.1
N-benzyl-4-[(phenylsulfonyl)amino]benzamide
Homo sapiens
-
IC50 above 0.1 mM
0.27
N-butyl-1-deoxynojirimycin
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-glucopyranoside as substrate
0.0246
N-butyl-4-[(phenylsulfonyl)amino]benzamide
Homo sapiens
-
-
0.044
N-butyl-isofagomine
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.00777
N-butyl-N'-(5-chloro-2-methoxyphenyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
Homo sapiens
-
-
0.002
N-butyldeoxynojirimycin
Homo sapiens
-
in 50 mM citrate buffer with 0.25% (v/v) Triton X-100 (pH 4.5)
0.00005
N-dodecyl-1-deoxynojirimycin
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.32
N-methyl-calystegine B2
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.0003 - 0.00066
N-nonyl-deoxynojirimycin
0.00646
N-phenyl-4-[(phenylsulfonyl)amino]benzamide
Homo sapiens
-
-
0.000009 - 0.0005
N-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]-6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
0.000015 - 0.04
N-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]-6-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
0.00003
N-[2-(3,6-dihydropyridin-1(2H)-yl)-4-methylquinolin-6-yl]cyclohexanecarboxamide
Homo sapiens
-
pH 5.9, at 22°C
0.00106
N-[2-(diethylamino)-4-methyl-1,2-dihydroquinolin-6-yl]-4-methylcyclohexanecarboxamide
Homo sapiens
-
-
0.000001 - 0.002
N-[5-(adamantan-1-yl-methoxy)pentyl]-L-ido-1-deoxynojirimycin
0.00002 - 0.00035
N-{3-[4-(cyanomethoxy)benzoyl]benzoyl}propylamido-1-deoxynojirimycin
0.028
nojirimycin bisulfite
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.00007
-
mutant E235A
0.00008
-
mutant E340A
0.0046
-
wild-type enzyme
0.02
-
expressed activity of wild-type enzyme
0.075 - 0.1
-
enzyme in cell lines from two patients with Niemann-Pick disease type C
0.4
-
enzyme in normal fibroblasts
3.57
-
-
16.6
-
-
26.7
-
-
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
4.5 - 5
-
-
4.8 - 5.8
-
-
5.2
-
assay at
6 - 6.6
-
-
7
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
3.5 - 6
-
pH 3.5: about 40% of maximum activity, pH 6.0: about 20% of maximum activity
4.5 - 7.5
-
-
5 - 8
-
pH 5.0: about 70% of maximum activity, pH 8.0: about 30% of maximum activity
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
mainly present in the upper epidermis, decreased in psoriatic skin compared to normal control, increased in lesional compared to non-lesional psoriatic skin
Manually annotated by BRENDA team
-
derived from Gaucher patients homozygous for N370S (non-neuronophatic form) or L444P (neuronophatic form)
Manually annotated by BRENDA team
-
recombinant glucocerebrosidase uptake by Gaucher disease human osteoblast culture model
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
similar enzyme
-
Manually annotated by BRENDA team
-
GBA2 is in part associated with the outer layer of plasma membranes
Manually annotated by BRENDA team
PDB
SCOP
CATH
ORGANISM
UNIPROT
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
52000
-
after deglycosylation, SDS-PAGE
57000
-
after deglycosylation, SDS-PAGE
60000
-
gel filtration, SDS-PAGE
62500
-
3 forms, 66000 Da and 59000 Da, gel filtration, SDS-PAGE
65000
-
x * 65000, SDS-PAGE
66000
-
3 forms, 62500 Da and 59000 Da, gel filtration, SDS-PAGE
68000
-
gel filtration, SDS-PAGE
69000
-
endo-H-resistant form, expressed in CHO cell
70000
-
gel filtration, SDS-PAGE
75000
-
gel filtration, SDS-PAGE
125000
-
radiation inactivation, Gaucher disease enzyme
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
?
-
x * 65000, SDS-PAGE
dimer
-
2 * 70000, SDS-PAGE
monomer
tetramer
-
4 * 60000, SDS-PAGE
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
cocrystallization with inhibitors using the micro-batch technique, with 0.2 M (NH4)2SO4/0.1 M Tris, pH 6.5, 25% (w/v) polyethylene glycol 3350 or 0.2 M NH4COOCH3/0.1 M HEPES, pH 7.5, 25% (w/v) polyethyleneglycol 3350
-
crystallization and X-ray analysis of recombinant enzyme
-
hanging drop vapour diffusion method with 0.1 M Tris-HCl buffer, pH 8.5, containing 0.2 M magnesium chloride, 27.5% PEG 3350, 5% glycerol, 0.5 M glucose or 0.5 M galactose
-
in complex beta-cyclodextrin and either 5-N,6-O-[N'-(n-octyl)iminomethylidene]nojirimycin or 5-N,6-S-[N'-(n-octyl)iminomethylidene]-6-thionojirimycin, microbatch under oil method, using 0.2 M (NH4)2SO4, 0.1 M Tris pH 6.5, and 25% (w/v) PEG3350
-
microbatch crystallization, the crystallization solution contains a 1:1 ratio of the concentrated enzyme solution and 2 M (NH4)2SO4, 0.1 M Bis-Tris pH 5.5
-
velaglucerase alfa, micro-batch crystallization under oil, using 1 M (NH4)2SO4/0.1 M HEPES, pH 7.0, containing 0.5% (w/v) PEG8000
-
X-ray structure of enzyme at 2.0 A resolution
-
X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide
-
pH STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
4
-
30 min, 10% loss of activity
136460
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
42
-
60 min, 10% loss of activity
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
chemical chaperones stabilize Gaucher disease-associated glucocerebroside variants N370S and G202R against misfolding, enabling their trafficking from the endoplasmic reticulum. The L44P variant is not chaperoned, likely because this mutation destabilizes a domain distinct from the catalytic domain
-
dithiothreitol stabilizes in later stages of chromatographic separation
-
freezing destroys activity
-
glycerol stabilizes in later stages of chromatographic separation
-
phospholipid, preincubation stabilizes
-
OXIDATION STABILITY
ORGANISM
UNIPROT
LITERATURE
forced oxidation of GCase that results in a 40-60% reduction in in vitro biological activity affects the stability of some key structural elements within the catalytic site. These changes in dynamics occur on a longer time scale that is irrelevant for catalysis, effectively ruling out loss of structure in the catalytic site as a major factor contributing to the reduction of the catalytic activity. Oxidation also leads to noticeable destabilization of conformation in remote protein segments on a much larger scale, which is likely to increase the aggregation propensity of GCase and affect its bioavailability
-
716853
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-20°C, 25% glycerol, several months, no loss of activity
-
-20°C, pH 6, 90% ethylene glycol, 20 days, no loss of activity
-
-43°C, 50% ethylene glycerol, several weeks, no loss of activity
-
0°C, 90% ethylene glycol, several weeks, no loss of activity
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
anti-FLAG M2 column chromatography
-
Hi-Trap Chelating HP column chromatography and Superdex 200 10/300 gel filtration
-
hydrophobic interaction chromatography
-
immunoaffinity chromatography
-
of the recombinant protein
-
PS20 ProteinChip Arrays with the immobilized anti-GC mAb 8E4
-
recombinant enzyme
-
recombinant enzyme from transgenic tobacco seeds
-
to homogeneity
-
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
alterations in enzyme gene are identified in 12 of the 57 subjects with Parkinson`s disease
-
expressed in Arabidopsis thaliana wild-type (Col-0) seeds
-
expressed in Chinese hamster ovary cells
-
expressed in Chinese hamster ovary cells and in transgenic carrot cells
-
expressed in CHO cells and Tn-5 cells
-
expressed in COS-7 cells
-
expressed in cultured plant cells
-
expressed in Escherichia coli BL21(DE3)pLysS cells
-
expressed in Mus musculus liver
-
expressed in Nicotiana tabacum cultivar Bright Yellow 2 cells
-
expressed in Sf9 insect cells
-
expression in Escherichia coli
-
expression in mouse fibroblasts NIH3T3
-
expression in NIH 3T3 cells
-
expression in Sf9 cells
-
expression of mutant and wild-type enzymes in murine cells
-
expression of wild-type and mutant enzymes by vaccinia based system, the wild-type and mutant enzymes are expressed in Gaucher fibroblast cell line L444P/S107L, HeLa G and BSC40, only enzyme-deficient fibroblasts are suitable for expression using plasmid transfection
-
gene-activated GCase is produced in an immortalized human cell line (HT-1080) utilizing targeted recombination with a promoter that activates the endogenous GCase in the presence of the mannosidase I inhibitor kifunensine, which results in a molecule with predominantly high-mannose-type glycans
-
overexpression in CHO cells, transfected with the tetracycline transactivation conditional expression system, majority of enzyme is secreted and overexpression in C2C12 cells, transducted with MFG-enzyme retrovirus
-
recombinant glucocerebrosidase uptake by Gaucher disease human osteoblast culture model
-
the mutated gene is subcloned into the mammalian expression vector pCR(R) 3.1 and expressed by transient transfection in COS cells
-
using fragments of the enzyme cDNA fused to the luciferase c DNA as a translational read-through reporter, the impact of synonymous codon usage bias on protein expression in Pichia pastoris as a potential system for the high-level heterologous production of human enzyme
-